Strategies for Treatment in Alexander Disease
Open Access
- 1 October 2010
- journal article
- review article
- Published by Elsevier BV in Neurotherapeutics
- Vol. 7 (4), 507-515
- https://doi.org/10.1016/j.nurt.2010.05.013
Abstract
No abstract availableKeywords
This publication has 91 references indexed in Scilit:
- Oligomers of Mutant Glial Fibrillary Acidic Protein (GFAP) Inhibit the Proteasome System in Alexander Disease Astrocytes, and the Small Heat Shock Protein αB-Crystallin Reverses the InhibitionOnline Journal of Public Health Informatics, 2010
- Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3Brain, 2009
- Rapamycin fed late in life extends lifespan in genetically heterogeneous miceNature, 2009
- Properties of astrocytes cultured from GFAP over-expressing and GFAP mutant miceExperimental Cell Research, 2009
- Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson's disease: Critical role for the astrocyteProceedings of the National Academy of Sciences of the United States of America, 2009
- Ubiquitination-mediated internalization and degradation of the astroglial glutamate transporter, GLT-1Neurochemistry International, 2008
- Internalization and degradation of the glutamate transporter GLT-1 in response to phorbol esterNeurochemistry International, 2008
- Lithium delays progression of amyotrophic lateral sclerosisProceedings of the National Academy of Sciences of the United States of America, 2008
- GFAP and its role in Alexander diseaseExperimental Cell Research, 2007
- The Alexander Disease–Causing Glial Fibrillary Acidic Protein Mutant, R416W, Accumulates into Rosenthal Fibers by a Pathway That Involves Filament Aggregation and the Association of αB-Crystallin and HSP27American Journal of Human Genetics, 2006